Umesh Mahantshetty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Umesh Mahantshetty has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
Reena Engineer
Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India
15 shared publicationsSupriya Chopra
Department of Radiation Oncology & Medical Physics, ACTREC, Tata Memorial Centre, HBNI, Mumbai, India
9 shared publicationsShyamkishore Shrivastava
Department of Radiation Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India
8 shared publicationsJamema Swamidas
Advanced Center for Cancer Treatment, Education and Research Tata memorial Center, HBNI, Mumbai, India
6 shared publicationsDeepak Deshpande
Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India
5 shared publicationsLavanya Gurram
Department of Radiation Oncology & Medical Physics, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India
5 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 17 (1) , 1-14
Clinical implementation of interstitial brachytherapy in early-stage oral cancer in a newly commissioned tertiary cancer center: Challenges and initial experience
High-dose-rate (HDR) interstitial brachytherapy (ISBT) is a curative treatment option for head and neck cancer patients. However, its overall utilization has been declining, particularly in newer cancer setups. This study investigated challenges in ISBT implementation, and reported initial outcomes of early-stage oral cancer patients in a newly established tertiary cancer center. After reviewing guidelines and addressing administrative requirements, ISBT program was launched. Key steps in the process included establishing brachytherapy suite, staff training, and optimizing workflows. Alongside standard protocols, additional procedures, such as clinical drawing templates, intra-oral ultrasound, and intra-oral spacers were implemented. From August 2020 to July 2022, 18 patients with early-stage (cT1-2N0M0) oral cancer (tongue = 13, lip = 3, buccal mucosa = 2) received treatment with either ISBT alone (n = 3) or external beam radiotherapy (EBRT), followed by ISBT with HDR cobalt-60 source (n = 15). Treatment characteristics, oncological outcomes, and morbidity profiles were analyzed. The median age of the cohort was 55 years (range, 29-75 years), with two-thirds of males. The majority had T1 stage (72.2%), with infiltrative growth pattern (72.2%). All patients with oral tongue cancer, 1 lip and 1 buccal mucosa cancer, received elective nodal irradiation with EBRT, followed by ISBT, achieving a total median EQD2 of 74 Gy. The remaining 3 patients (2 with lip and 1 with buccal mucosa primary) received ISBT alone. Post-treatment complete response was observed in 17 patients (94.4%), with no cases of acute toxicity > grade 2. At a median follow-up of 32 months, an overall 3-year local-regional control and overall survival rates were 67.9% and 72.7%, respectively. One patient developed grade 3 myelopathy, and one grade 3 osteoradionecrosis. Implementing ISBT in a newly established cancer center is feasible and effective for early-stage oral cancer, providing moderate oncological outcomes with manageable toxicity profile.
- 1 January 2025
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 17 (1) , 1-14
Open AccessClinical implementation of interstitial brachytherapy in early-stage oral cancer in a newly commissioned tertiary cancer center: Challenges and initial experience
High-dose-rate (HDR) interstitial brachytherapy (ISBT) is a curative treatment option for head and neck cancer patients. However, its overall utilization has been declining, particularly in newer cancer setups. This study investigated challenges in ISBT implementation, and reported initial outcomes of early-stage oral cancer patients in a newly established tertiary cancer center. After reviewing guidelines and addressing administrative requirements, ISBT program was launched. Key steps in the process included establishing brachytherapy suite, staff training, and optimizing workflows. Alongside standard protocols, additional procedures, such as clinical drawing templates, intra-oral ultrasound, and intra-oral spacers were implemented. From August 2020 to July 2022, 18 patients with early-stage (cT1-2N0M0) oral cancer (tongue = 13, lip = 3, buccal mucosa = 2) received treatment with either ISBT alone (n = 3) or external beam radiotherapy (EBRT), followed by ISBT with HDR cobalt-60 source (n = 15). Treatment characteristics, oncological outcomes, and morbidity profiles were analyzed. The median age of the cohort was 55 years (range, 29-75 years), with two-thirds of males. The majority had T1 stage (72.2%), with infiltrative growth pattern (72.2%). All patients with oral tongue cancer, 1 lip and 1 buccal mucosa cancer, received elective nodal irradiation with EBRT, followed by ISBT, achieving a total median EQD2 of 74 Gy. The remaining 3 patients (2 with lip and 1 with buccal mucosa primary) received ISBT alone. Post-treatment complete response was observed in 17 patients (94.4%), with no cases of acute toxicity > grade 2. At a median follow-up of 32 months, an overall 3-year local-regional control and overall survival rates were 67.9% and 72.7%, respectively. One patient developed grade 3 myelopathy, and one grade 3 osteoradionecrosis. Implementing ISBT in a newly established cancer center is feasible and effective for early-stage oral cancer, providing moderate oncological outcomes with manageable toxicity profile.
- Open Access
- 10 July 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (12) , 1940-1945
Are we making progress in curing advanced cervical cancer—again?
Major improvements in radiotherapy over the past two decades in the definitive treatment of locally advanced cervical cancer have significantly improved loco-regional control and survival, whereas little progress has been made with chemotherapy since the implementation of concomitant cisplatin 25 years ago. However, the randomized study INTERLACE (A phase III multicenter trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with locally advanced cervical cancer) of neoadjuvant chemotherapy presented recently, has shown significant improvement in survival with the use of six cycles of weekly carboplatin and paclitaxel. Although INTERLACE is yet to be published, neoadjuvant chemotherapy is already being advocated as the new standard, and studies are being designed with neoadjuvant chemotherapy followed by chemoradiation and brachytherapy as the standard arm. It is noteworthy that INTERLACE was initiated before the improvements in radiotherapy mentioned above were broadly implemented. The survival rate in the standard arm of INTERLACE was therefore inferior to the results obtained with the latest state-of-the-art external beam radiotherapy and image guided adaptive brachytherapy (EMBRACE, Magnetic Resonance Imaging (MRI)-Guided Brachytherapy in Locally Advanced Cervical Cancer). Moreover, patient selection impedes the comparison of INTERLACE with other studies as the patients included in INTERLACE were younger, had better performance status, and had less advanced disease than in other studies. Notably patients with involved para-aortic nodes were excluded. In this review, we discuss neoadjuvant chemotherapy in the frame of the EMBRACE studies and show how the impact of modern radiotherapy and patient selection affects the interpretation of the results of INTERLACE. This has led us to conclude that neoadjuvant chemotherapy is not needed for the majority of patients with cervical cancer treated with definitive modern radiotherapy, and may cause harm. However, it is possible that short course neoadjuvant chemotherapy may benefit a minor subgroup of patients who need to be identified. Comprehensive understanding, including cost utility analyses, are needed to draw conclusions regarding the potential benefit of neoadjuvant chemotherapy in low and middle income countries with limited access to modern radiotherapy.
- 10 July 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (12) , 1940-1945
Open AccessAre we making progress in curing advanced cervical cancer—again?
Major improvements in radiotherapy over the past two decades in the definitive treatment of locally advanced cervical cancer have significantly improved loco-regional control and survival, whereas little progress has been made with chemotherapy since the implementation of concomitant cisplatin 25 years ago. However, the randomized study INTERLACE (A phase III multicenter trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with locally advanced cervical cancer) of neoadjuvant chemotherapy presented recently, has shown significant improvement in survival with the use of six cycles of weekly carboplatin and paclitaxel. Although INTERLACE is yet to be published, neoadjuvant chemotherapy is already being advocated as the new standard, and studies are being designed with neoadjuvant chemotherapy followed by chemoradiation and brachytherapy as the standard arm. It is noteworthy that INTERLACE was initiated before the improvements in radiotherapy mentioned above were broadly implemented. The survival rate in the standard arm of INTERLACE was therefore inferior to the results obtained with the latest state-of-the-art external beam radiotherapy and image guided adaptive brachytherapy (EMBRACE, Magnetic Resonance Imaging (MRI)-Guided Brachytherapy in Locally Advanced Cervical Cancer). Moreover, patient selection impedes the comparison of INTERLACE with other studies as the patients included in INTERLACE were younger, had better performance status, and had less advanced disease than in other studies. Notably patients with involved para-aortic nodes were excluded. In this review, we discuss neoadjuvant chemotherapy in the frame of the EMBRACE studies and show how the impact of modern radiotherapy and patient selection affects the interpretation of the results of INTERLACE. This has led us to conclude that neoadjuvant chemotherapy is not needed for the majority of patients with cervical cancer treated with definitive modern radiotherapy, and may cause harm. However, it is possible that short course neoadjuvant chemotherapy may benefit a minor subgroup of patients who need to be identified. Comprehensive understanding, including cost utility analyses, are needed to draw conclusions regarding the potential benefit of neoadjuvant chemotherapy in low and middle income countries with limited access to modern radiotherapy.
- Open Access
- 30 January 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 181, 109501
Association of persistent morbidity after radiotherapy with quality of life in locally advanced cervical cancer survivors
- 30 January 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 181, 109501
Open AccessAssociation of persistent morbidity after radiotherapy with quality of life in locally advanced cervical cancer survivors
- 1 November 2021
- Published by Elsevier in Brachytherapy
- Vol. 20 (6) , 1146-1155
Low-Dose-Rate versus High-Dose-Rate intracavitary brachytherapy in cervical cancer - Final Results of a Phase III randomized trial
- 1 November 2021
- Published by Elsevier in Brachytherapy
- Vol. 20 (6) , 1146-1155
Low-Dose-Rate versus High-Dose-Rate intracavitary brachytherapy in cervical cancer - Final Results of a Phase III randomized trial
- 1 September 2021
- Published by Elsevier in Clinical Oncology
- Vol. 33 (9) , e363-e371
Incidence, Treatment and Outcomes of Cervical Cancer in Low- and Middle-income Countries
- 1 September 2021
- Published by Elsevier in Clinical Oncology
- Vol. 33 (9) , e363-e371
Incidence, Treatment and Outcomes of Cervical Cancer in Low- and Middle-income Countries
- Top Cited PapersOpen Access
- 18 May 2021
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 160, 273-284
IBS-GEC ESTRO-ABS recommendations for CT based contouring in image guided adaptive brachytherapy for cervical cancer
- 18 May 2021
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 160, 273-284
Top Cited PapersOpen AccessIBS-GEC ESTRO-ABS recommendations for CT based contouring in image guided adaptive brachytherapy for cervical cancer
- 20 November 2020
- Published by Morressier GmbH
RISK FACTORS AFFECTING ONCOLOGICAL OUTCOMES IN VULVAR CANCER UNDERGOING PRIMARY SURGERY: CASE SERIES FROM A TERTIARY CANCER CENTRE
Risk factors affecting oncological outcomes in vulvar cancer undergoing primary surgery: Case series from a tertiary cancer centre Objective: To |
- 20 November 2020
- Published by Morressier GmbH
RISK FACTORS AFFECTING ONCOLOGICAL OUTCOMES IN VULVAR CANCER UNDERGOING PRIMARY SURGERY: CASE SERIES FROM A TERTIARY CANCER CENTRE
Risk factors affecting oncological outcomes in vulvar cancer undergoing primary surgery: Case series from a tertiary cancer centre Objective: To |